Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-20117 + mFOLFOX6
- Development stage
- Unknown
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HS-20117 + mFOLFOX6 is a combination therapy under clinical investigation for advanced solid tumors, including non-small-cell lung cancer (NSCLC) and colorectal cancer. HS-20117 (also known as PM1080) is a fully-human bispecific antibody that targets both the epidermal growth factor receptor (EGFR) and c-Met, designed to inhibit tumor growth by blocking these pathways. It is an IgG1-like heterodimeric antibody developed by Biotheus and licensed to Hansoh Pharma for further development, particularly in antibody-drug conjugate formats[1][2][3][4][5]. The mFOLFOX6 regimen consists of three chemotherapeutic agents: oxaliplatin, folinic acid (leucovorin), and fluorouracil (5-FU), commonly used as first-line treatment in colorectal cancer. This regimen works by destroying rapidly dividing cells through different mechanisms of action[6][8]. The combination aims to leverage the targeted anti-tumor activity of HS-20117 with the cytotoxic effects of standard chemotherapy.
02
Targets
DNAEGFR (Epidermal growth factor receptor)MET (Mesenchymal-epithelial transition factor receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on HS-20117 + mFOLFOX6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-20117 + mFOLFOX6.